Pharmaceutical

Keytruda combination treatment for NSCLC falls short in Phase III

The Phase III KEYLYNK-006 study evaluating a Keytruda/Lynparza combination treatment failed to meet its primary endpoints.

Mar 22, 2024 - 00:00
Keytruda combination treatment for NSCLC falls short in Phase III
The Phase III KEYLYNK-006 study evaluating a Keytruda/Lynparza combination treatment failed to meet its primary endpoints.
Read the original article

Tags:

Previous Article

Nouscom extends Series C round to $82m for cancer vaccine trials

Next Article

Molecular glues are the latest craze in pharma research, but what are they?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Risk sharing agreements soar as market access risk increases

Risk sharing agreements soar as market access risk incr...

Mar 19, 2023

STAT+: Startup Alumis raises $259 million as it prepares for psoriasis trial

STAT+: Startup Alumis raises $259 million as it prepare...

Mar 6, 2024

STAT+: What the Covid-19 pandemic can teach us about drug patents

STAT+: What the Covid-19 pandemic can teach us about dr...

May 3, 2023